234 related articles for article (PubMed ID: 31753106)
1. Management of Locoregionally Advanced Melanoma.
Pointer DT; Zager JS
Surg Clin North Am; 2020 Feb; 100(1):109-125. PubMed ID: 31753106
[TBL] [Abstract][Full Text] [Related]
2. Intralesional therapy as a treatment for locoregionally metastatic melanoma.
Miura JT; Zager JS
Expert Rev Anticancer Ther; 2018 Apr; 18(4):399-408. PubMed ID: 29466885
[TBL] [Abstract][Full Text] [Related]
3. Regional therapies for locoregionally advanced and unresectable melanoma.
Weitman ES; Zager JS
Clin Exp Metastasis; 2018 Aug; 35(5-6):495-502. PubMed ID: 29736626
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
Burke EE; Zager JS
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
[TBL] [Abstract][Full Text] [Related]
5. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
6. Current treatment of locoregional recurrence of melanoma.
Squires MH; Delman KA
Curr Oncol Rep; 2013 Oct; 15(5):465-72. PubMed ID: 23907518
[TBL] [Abstract][Full Text] [Related]
7. Intralesional immunotherapy as a strategy to treat melanoma.
Nouri N; Garbe C
Expert Opin Biol Ther; 2016; 16(5):619-26. PubMed ID: 26898656
[TBL] [Abstract][Full Text] [Related]
8. Intralesional therapy for metastatic melanoma.
Sloot S; Rashid OM; Zager JS
Expert Opin Pharmacother; 2014 Dec; 15(18):2629-39. PubMed ID: 25381015
[TBL] [Abstract][Full Text] [Related]
9. Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress.
DePalo DK; Zager JS
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900196
[TBL] [Abstract][Full Text] [Related]
10. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
[TBL] [Abstract][Full Text] [Related]
11. Management of in-transit melanoma metastases: a review.
Nan Tie E; Henderson MA; Gyorki DE
ANZ J Surg; 2019 Jun; 89(6):647-652. PubMed ID: 30414233
[TBL] [Abstract][Full Text] [Related]
12. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
Rothermel LD; Zager JS
Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
[TBL] [Abstract][Full Text] [Related]
13. Regional therapies for in-transit disease.
Speicher PJ; Meriwether CH; Tyler DS
Surg Oncol Clin N Am; 2015 Apr; 24(2):309-22. PubMed ID: 25769714
[TBL] [Abstract][Full Text] [Related]
14. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
15. Developments in Intralesional Therapy for Metastatic Melanoma.
Sloot S; Rashid OM; Sarnaik AA; Zager JS
Cancer Control; 2016 Jan; 23(1):12-20. PubMed ID: 27009452
[TBL] [Abstract][Full Text] [Related]
16. Local and intralesional therapy of in-transit melanoma metastases.
Testori A; Faries MB; Thompson JF; Pennacchioli E; Deroose JP; van Geel AN; Verhoef C; Verrecchia F; Soteldo J
J Surg Oncol; 2011 Sep; 104(4):391-6. PubMed ID: 21858834
[TBL] [Abstract][Full Text] [Related]
17. [Study and treatment of locally advanced melanoma].
Moreno-RamÃrez D; de la Cruz L; Ferrándiz L; Camacho FM
Actas Dermosifiliogr; 2009 Nov; 100(9):767-79. PubMed ID: 19889298
[TBL] [Abstract][Full Text] [Related]
18. Locoregional cutaneous metastases of malignant melanoma and their management.
Wolf IH; Richtig E; Kopera D; Kerl H
Dermatol Surg; 2004 Feb; 30(2 Pt 2):244-7. PubMed ID: 14871216
[TBL] [Abstract][Full Text] [Related]
19. Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma.
Read RL; Thompson JF
Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1107-1119. PubMed ID: 31687857
[No Abstract] [Full Text] [Related]
20. Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response.
Gingrich AA; Kirane AR
Surg Oncol Clin N Am; 2020 Jul; 29(3):467-483. PubMed ID: 32482321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
